| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037940187 |
| P356 | DOI | 10.1186/1465-9921-7-70 |
| P932 | PMC publication ID | 1479815 |
| P698 | PubMed publication ID | 16669999 |
| P5875 | ResearchGate publication ID | 7110592 |
| P50 | author | Robert A Stockley | Q96815228 |
| P2093 | author name string | Martin J Sevenoaks | |
| P2860 | cites work | Cancer cachexia | Q81330751 |
| Helicobacter pylori seroprevalence in patients with chronic obstructive pulmonary disease | Q81445914 | ||
| TNFR2 gene polymorphism in coronary artery disease | Q81605664 | ||
| Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease | Q24247745 | ||
| Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway | Q24290228 | ||
| Tumor necrosis factor-alpha and muscle wasting: a cellular perspective | Q24806646 | ||
| Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report | Q27861020 | ||
| Oxidative Stress in Chronic Obstructive Pulmonary Disease | Q28747125 | ||
| Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation | Q29547453 | ||
| Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary | Q29614692 | ||
| The metabolic syndrome--a new worldwide definition | Q29615125 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance | Q29619774 | ||
| Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese | Q32132515 | ||
| Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia | Q33946056 | ||
| The role of C-reactive protein in cardiovascular disease risk | Q34011157 | ||
| Cachexia | Q34061258 | ||
| Biology of cachexia | Q34065627 | ||
| Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus | Q34142970 | ||
| Inflammatory markers and the risk of coronary heart disease in men and women | Q34376967 | ||
| Wasting as independent risk factor for mortality in chronic heart failure | Q34421966 | ||
| Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms | Q34446644 | ||
| Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. | Q34509276 | ||
| The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease | Q34546085 | ||
| Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection | Q35008871 | ||
| Insulin resistance and chronic cardiovascular inflammatory syndrome | Q35146311 | ||
| American College of Endocrinology position statement on the insulin resistance syndrome. | Q35201721 | ||
| Which spirometric indices best predict subsequent death from chronic obstructive pulmonary disease? | Q35534051 | ||
| Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis | Q35536791 | ||
| Total daily energy expenditure relative to resting energy expenditure in clinically stable patients with COPD. | Q35563842 | ||
| Systemic inflammation in chronic obstructive pulmonary disease | Q35585601 | ||
| Nutritional and metabolic modulation in chronic obstructive pulmonary disease management | Q35585633 | ||
| A novel pathway to the manifestations of metabolic syndrome | Q35674454 | ||
| Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality | Q36236967 | ||
| Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha | Q37271202 | ||
| Risk of myocardial infarction and stroke after acute infection or vaccination | Q39471364 | ||
| Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? | Q40815170 | ||
| Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein | Q41098875 | ||
| Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease | Q41207115 | ||
| Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). | Q43586296 | ||
| The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study | Q43748961 | ||
| Effects of TNF-alpha on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations | Q43954639 | ||
| Antiinflammatory and antiarteriosclerotic effects of pioglitazone | Q44201670 | ||
| Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events | Q44216708 | ||
| Study of gastroduodenal abnormalities in chronic bronchitis and emphysema | Q44661025 | ||
| The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients | Q44671845 | ||
| Tumor necrosis factor-alpha drives 70% of cigarette smoke-induced emphysema in the mouse | Q44927002 | ||
| Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study. | Q45173631 | ||
| Oxidative stress and respiratory muscle dysfunction in severe chronic obstructive pulmonary disease | Q45285612 | ||
| Pathophysiology of protein-energy wasting in chronic renal failure | Q46186695 | ||
| Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males | Q46414701 | ||
| Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects | Q46463135 | ||
| Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease | Q47286648 | ||
| Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. | Q47925592 | ||
| Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease | Q48016346 | ||
| Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. | Q50538129 | ||
| Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. | Q50853568 | ||
| NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. | Q50920620 | ||
| Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. | Q51557746 | ||
| Mortality after hospitalization for COPD. | Q51717351 | ||
| Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. | Q53586617 | ||
| Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. | Q53941037 | ||
| The Relation Between Peripheral Blood Leukocyte Counts and Respiratory Symptoms, Atopy, Lung Function, and Airway Responsiveness in Adults | Q57415805 | ||
| Chronic Obstructive Pulmonary Disease, Asthma, and Risk of Type 2 Diabetes in Women | Q57749967 | ||
| Systemic oxidative stress in asthma, COPD, and smokers | Q58317045 | ||
| Wasting in HIV infection and AIDS | Q58463593 | ||
| Systemic effects of chronic obstructive pulmonary disease | Q58840542 | ||
| Local and Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease | Q59669053 | ||
| Multifaceted roles of TNF-? in myoblast destruction: A multitude of signal transduction pathways | Q60275504 | ||
| Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH | Q61716813 | ||
| Comment on the provisional report from the WHO consultation | Q62127032 | ||
| Muscle wasting in emphysema | Q67978679 | ||
| Ventilatory function in chronic peptic ulcer. A controlled study of ventilatory function in patients with gastric and duodenal ulcer | Q68889686 | ||
| Binding of human C-reactive protein to mouse macrophages is mediated by distinct receptors | Q69965580 | ||
| Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial | Q71723693 | ||
| The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state | Q73189689 | ||
| Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease | Q73280499 | ||
| The activity of cytochrome oxidase is increased in circulating lymphocytes of patients with chronic obstructive pulmonary disease, asthma, and chronic arthritis | Q73321285 | ||
| The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease | Q73675027 | ||
| Polymorphism of the tumor necrosis factor-alpha receptor 2 gene is associated with obesity, leptin levels, and insulin resistance in young subjects and diet-treated type 2 diabetic patients | Q73857663 | ||
| Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels | Q74225996 | ||
| Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease | Q74363350 | ||
| Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study | Q77769452 | ||
| Serum tumour necrosis factor-alpha is increased in patients with Helicobacter pylori infection and CagA antibodies | Q78057493 | ||
| P921 | main subject | chronic obstructive pulmonary disease | Q199804 |
| phenotype | Q104053 | ||
| P304 | page(s) | 70 | |
| P577 | publication date | 2006-05-02 | |
| P1433 | published in | Respiratory Research | Q7315904 |
| P1476 | title | Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype? | |
| P478 | volume | 7 |
| Q42027214 | A new inflammation marker of chronic obstructive pulmonary disease-adiponectin. |
| Q35220025 | Airway inflammation contributes to health status in COPD: a cross-sectional study. |
| Q38399184 | An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease |
| Q96135220 | An overview of exacerbations of chronic obstructive pulmonary disease: Can tests of small airways' function guide diagnosis and management? |
| Q37675233 | Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study |
| Q42764832 | Biomarkers in COPD: time for a deep breath |
| Q27690280 | Biomarkers in chronic obstructive pulmonary disease: confusing or useful? |
| Q37231865 | COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention |
| Q37139528 | COPD as a systemic disease |
| Q36889904 | Chronic Obstructive Pulmonary Disease is associated with risk of Chronic Kidney Disease: A Nationwide Case-Cohort Study |
| Q36446491 | Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk |
| Q64386432 | Chronic low-grade systemic inflammation causes DNA damage in the lungs of mice |
| Q38262835 | Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment |
| Q36443665 | Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities |
| Q33600138 | Chronic obstructive pulmonary disease: towards pharmacogenetics |
| Q34629921 | Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease |
| Q41432972 | Diabetes risks and outcomes in chronic obstructive pulmonary disease patients: Two nationwide population-based retrospective cohort studies |
| Q38604749 | Does Improving Exercise Capacity and Daily Activity Represent the Holistic Perspective of a New COPD Approach? |
| Q61798726 | Dual-Modal In Vivo Fluorescence/Photoacoustic Microscopy Imaging of Inflammation Induced by GFP-Expressing Bacteria |
| Q50983469 | Effects of Ergosterol on COPD in Mice via JAK3/STAT3/NF-κB Pathway. |
| Q37673154 | Effects of an Encapsulated Fruit and Vegetable Juice Concentrate on Obesity-Induced Systemic Inflammation: A Randomised Controlled Trial |
| Q61809267 | Evaluation of plasma antimicrobial peptide LL-37 and nuclear factor-kappaB levels in stable chronic obstructive pulmonary disease |
| Q26828976 | Excess costs of comorbidities in chronic obstructive pulmonary disease: a systematic review |
| Q38203516 | Exhaled nitric oxide as a biomarker in COPD and related comorbidities |
| Q58877168 | From COPD to chronic systemic inflammatory syndrome? |
| Q80684055 | Genetics of chronic obstructive pulmonary disease |
| Q38119867 | Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services |
| Q44956259 | High-resolution mass spectrometry proteomics for the identification of candidate plasma protein biomarkers for chronic obstructive pulmonary disease |
| Q35984248 | Histone deacetylase activity is decreased in peripheral blood monocytes in patients with COPD. |
| Q33416183 | IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study |
| Q36797618 | INDACO project: a pilot study on incidence of comorbidities in COPD patients referred to pneumology units |
| Q51765768 | Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. |
| Q45017800 | Impact of long-term treatment with low-dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: aggravating or beneficial? |
| Q35741439 | Increased Peripheral Blood Pro-Inflammatory/Cytotoxic Lymphocytes in Children with Bronchiectasis |
| Q80575987 | Increased intracellular T helper 1 proinflammatory cytokine production in peripheral blood, bronchoalveolar lavage and intraepithelial T cells of COPD subjects |
| Q51595696 | Increased risk of chronic obstructive pulmonary disease among patients with Helicobacter pylori infection: a population-based cohort study. |
| Q36974700 | Inflammation and lung carcinogenesis: applying findings in prevention and treatment. |
| Q35897669 | Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer |
| Q37096361 | Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment |
| Q48611059 | Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease |
| Q37681569 | Inhaled corticosteroids in chronic obstructive pulmonary disease: a review. |
| Q42212096 | Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease |
| Q50554528 | Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. |
| Q36339373 | NF-κB-dependent airway inflammation triggers systemic insulin resistance |
| Q38491004 | On the importance of small changes in RNA expression |
| Q34854354 | Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report |
| Q37551125 | Original Research: Extract of Bambusae Caulis in Taeniam inhibits cigarette smoke-induced pulmonary and intestinal inflammation |
| Q27693862 | Pulmonary-intestinal cross-talk in mucosal inflammatory disease |
| Q39270415 | Relationship between femur neck bone mineral density and prevalent chronic obstructive pulmonary disease (COPD) or COPD mortality in older non-Hispanic white adults from NHANES III. |
| Q28066773 | Repurposing Treatments to Enhance Innate Immunity. Can Statins Improve Neutrophil Functions and Clinical Outcomes in COPD? |
| Q90353425 | Risk of chronic obstructive pulmonary disease in healthy individuals with high C-reactive protein levels by smoking status: a population-based cohort study in Korea |
| Q43061644 | Roflumilast: systemic therapy for chronic obstructive pulmonary disease |
| Q42146567 | Role of Serum Interleukin 6, Albumin and C-Reactive Protein in COPD Patients |
| Q42218227 | Roles of macrophage stimulating protein and tyrosine kinase receptor RON in smoke-induced airway inflammation of rats |
| Q39428853 | Serum C-reactive protein level and distribution in chronic obstructive pulmonary disease versus healthy controls: a case-control study from Iran. |
| Q33842487 | Smoking and lung cancer: the role of inflammation |
| Q37290506 | Statins Dose-Dependently Exert Significant Chemopreventive Effects Against Various Cancers in Chronic Obstructive Pulmonary Disease Patients: A Population-Based Cohort Study. |
| Q46225372 | Stronger bone correlates with African admixture in African-American women |
| Q33802207 | Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives |
| Q38056532 | Systemic inflammatory biomarkers and co-morbidities of chronic obstructive pulmonary disease |
| Q33760782 | Targeting peripheral blood pro-inflammatory cytotoxic lymphocytes by inhibiting CD137 expression: novel potential treatment for COPD |
| Q87695964 | The Importance of Neutrophil-to-Lymphocyte Ratio in Chronic Obstructive Pulmonary Disease |
| Q36782392 | The TNFalpha gene relates to clinical phenotype in alpha-1-antitrypsin deficiency |
| Q51373002 | The association of low bone mineral density with systemic inflammation in clinically stable COPD. |
| Q36926305 | The drug efflux pump Pgp1 in pro-inflammatory lymphocytes is a target for novel treatment strategies in COPD. |
| Q35113365 | The genetics of chronic obstructive pulmonary disease. |
| Q37389399 | The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease |
| Q38208185 | The path to personalised medicine in COPD. |
| Q46854577 | The physiological characteristics of community-dwelling elderly Japanese with airflow limitation: a cross-sectional study |
| Q37168309 | The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year |
| Q47352116 | Unilateral pulmonary oedema after minimally invasive mitral valve surgery: a single-centre experience. |
| Q36838782 | Update in chronic obstructive pulmonary disease 2006. |
| Q37252704 | Vitamin D deficiency and chronic lung disease |
| Q36345260 | Vitamin D deficiency, smoking, and lung function in the Normative Aging Study |
| Q82707743 | [COPD and endocrine and metabolic alterations] |
| Q51158797 | [Comorbidities in COPD]. |
| Q93219507 | [Prevalence and characteristics of chronic obstructive pulmonary disease in non-smokers] |
Search more.